Optimising the Timing of whooping cough Immunisation in MUMs (OpTIMUM): A randomised controlled trial investigating the timing of pertussis vaccination in pregnancy
Optimising the Timing of whooping cough Immunisation in MUMs (OpTIMUM): A randomised controlled trial investigating the timing of pertussis vaccination in pregnancy
Background: Pertussis is a highly infectious respiratory illness caused by the bacteria Bordetella pertussis. A resurgence of pertussis, even in countries with good vaccine coverage, has led to an increase in infant deaths. In response to this, many countries have introduced pertussis vaccination in pregnancy. This strategy is effective at preventing infant disease, but there remains uncertainty about what gestational timing is best to ensure maximal protection of the infant. These uncertainties are the rationale for this randomised controlled trial and a sub-study investigating pertussis-specific antibody in breastmilk.
Protocol: We will recruit 354 pregnant women and will randomise them to receive their pertussis vaccination in one of three gestational age windows: ≤23+6, 24-27+6 and 28-31+6 weeks of gestation. Vaccination will be with Boostrix-IPV® and participants will be asked to complete a symptom diary for seven days following vaccination. Blood sampling will be performed prior to vaccination, two weeks following vaccination and at the time of delivery. A cord blood sample will be collected at delivery and a blood sample collected from the infant 4-10 weeks after completion of the primary immunisations. Individuals participating in the breastmilk sub-study will provide a sample of colostrum within 48 hours of delivery and samples of breastmilk at two weeks and around five-six months. Blood samples will be analysed using enzyme linked immunosorbent assay (ELISA) techniques for pertussis toxin, filamentous haemagglutinin and pertactin. A subset of serum samples will also be analysed using a functional assay. Colostrum and breastmilk samples will be analysed using functional assays.
Discussion: Although pertussis vaccination has been shown to be safe and effective in pregnancy there remains debate about the optimal timing for the administration during pregnancy. This study will investigate antibody responses in serum and breastmilk when vaccination is performed in three different time periods.
Clinicaltrials.gov registration: NCT03908164 (09/04/2019)
Calvert, Anna
03bc971b-ed4f-4c6c-bcb5-29943bff1661
Karampelas, Konstantinos
910e7ee0-73a3-4d32-8428-b93b0d01cdcc
Andrews, Nick
1c70a9ec-8abb-4216-912c-33291130f542
England, Anna
590a306a-2173-4799-80b8-d09e44854f59
Hallis, Bassam
f6388da1-bf85-457f-b30a-c0849034024c
Jones, Christine E
48229079-8b58-4dcb-8374-d9481fe7b426
Khalil, Asma
f1350e97-84da-49f1-a86f-7f1a109995b0
Le Doare, Kirsty
9424dc5c-4484-41d3-86dd-29cfaffb43f5
Matheson, Mary
00059ccd-6077-42af-a8a2-a3c3b31e5eca
Snape, Matthew D.
184fac36-63b2-40d2-be21-c972f41d07ab
Heath, Paul T.
fce44186-c98d-4bdf-8d60-d0f89fff2ce9
Calvert, Anna
03bc971b-ed4f-4c6c-bcb5-29943bff1661
Karampelas, Konstantinos
910e7ee0-73a3-4d32-8428-b93b0d01cdcc
Andrews, Nick
1c70a9ec-8abb-4216-912c-33291130f542
England, Anna
590a306a-2173-4799-80b8-d09e44854f59
Hallis, Bassam
f6388da1-bf85-457f-b30a-c0849034024c
Jones, Christine E
48229079-8b58-4dcb-8374-d9481fe7b426
Khalil, Asma
f1350e97-84da-49f1-a86f-7f1a109995b0
Le Doare, Kirsty
9424dc5c-4484-41d3-86dd-29cfaffb43f5
Matheson, Mary
00059ccd-6077-42af-a8a2-a3c3b31e5eca
Snape, Matthew D.
184fac36-63b2-40d2-be21-c972f41d07ab
Heath, Paul T.
fce44186-c98d-4bdf-8d60-d0f89fff2ce9
Calvert, Anna, Karampelas, Konstantinos, Andrews, Nick, England, Anna, Hallis, Bassam, Jones, Christine E, Khalil, Asma, Le Doare, Kirsty, Matheson, Mary, Snape, Matthew D. and Heath, Paul T.
(2021)
Optimising the Timing of whooping cough Immunisation in MUMs (OpTIMUM): A randomised controlled trial investigating the timing of pertussis vaccination in pregnancy.
The Lancet Microbe.
(doi:10.12688/wellcomeopenres.16767.1).
Abstract
Background: Pertussis is a highly infectious respiratory illness caused by the bacteria Bordetella pertussis. A resurgence of pertussis, even in countries with good vaccine coverage, has led to an increase in infant deaths. In response to this, many countries have introduced pertussis vaccination in pregnancy. This strategy is effective at preventing infant disease, but there remains uncertainty about what gestational timing is best to ensure maximal protection of the infant. These uncertainties are the rationale for this randomised controlled trial and a sub-study investigating pertussis-specific antibody in breastmilk.
Protocol: We will recruit 354 pregnant women and will randomise them to receive their pertussis vaccination in one of three gestational age windows: ≤23+6, 24-27+6 and 28-31+6 weeks of gestation. Vaccination will be with Boostrix-IPV® and participants will be asked to complete a symptom diary for seven days following vaccination. Blood sampling will be performed prior to vaccination, two weeks following vaccination and at the time of delivery. A cord blood sample will be collected at delivery and a blood sample collected from the infant 4-10 weeks after completion of the primary immunisations. Individuals participating in the breastmilk sub-study will provide a sample of colostrum within 48 hours of delivery and samples of breastmilk at two weeks and around five-six months. Blood samples will be analysed using enzyme linked immunosorbent assay (ELISA) techniques for pertussis toxin, filamentous haemagglutinin and pertactin. A subset of serum samples will also be analysed using a functional assay. Colostrum and breastmilk samples will be analysed using functional assays.
Discussion: Although pertussis vaccination has been shown to be safe and effective in pregnancy there remains debate about the optimal timing for the administration during pregnancy. This study will investigate antibody responses in serum and breastmilk when vaccination is performed in three different time periods.
Clinicaltrials.gov registration: NCT03908164 (09/04/2019)
Text
OpTIMUM LANCET Microbe_final version
- Accepted Manuscript
Restricted to Repository staff only
Request a copy
Text
9008b7e1-200c-48da-9241-f665374cb804_16767_-_anna_calvert
- Version of Record
More information
e-pub ahead of print date: 14 June 2021
Identifiers
Local EPrints ID: 472980
URI: http://eprints.soton.ac.uk/id/eprint/472980
PURE UUID: 95270b50-c9bf-48a5-89c8-7aeff1c75a50
Catalogue record
Date deposited: 06 Jan 2023 17:34
Last modified: 17 Mar 2024 03:45
Export record
Altmetrics
Contributors
Author:
Anna Calvert
Author:
Konstantinos Karampelas
Author:
Nick Andrews
Author:
Anna England
Author:
Bassam Hallis
Author:
Asma Khalil
Author:
Kirsty Le Doare
Author:
Mary Matheson
Author:
Matthew D. Snape
Author:
Paul T. Heath
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics